Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose

Table 1 Neutralizing antibody titers of rhesus monkeys selected as SHIVIG donors

RM	Homologous clade C viruses		Heterologous clade C viruses						Heterologous clade B viruses
RM	SHIV-1157ip (early, tier 1)	SHIV-1157ipd3N4 (late, tier 2)	HIV_ZM135M	HIV_1084i	HIV_pIndieC	HIV_ZM233M.PB6	HIV_ZM109F	SHIV-2873Nip	SHIV_SF162P3	HIV_SF162.LS	HIV_NL4-3	SHIV_89.6P
RAo-8	2,048	>640	<20		128	42	<20	>640	<40	220	32
RCt-10	360	>640						>640		6,500
RHo-10	250	>640						>640
RHy-9	600	>10,240	<20	100	90	<20	<20	>640		173		100
RJa-9	1,800	>10,240	<20		128	59	22	2,048	68	35,770	128
RLu-9	>1,280	>640	<20	50	47	<20	<20	>640		58		75
RMf-9	2,048	>640	<20		128	<20	35	>640	78	18,303	128
RPo-10	200	>640						>640
RTs-7	2,048	>640			128			>640			32

NAb titers (reciprocal dilution of sera giving 50% reduction in virus replication) were determined in TZM-bl cells or, for SHIV-1157ipd3N4 and SHIV-2873Nip, in human PBMC-based assays. The SHIVs were prepared in RM PBMC; HIV_1084i, HIV_NL4-3 and HIV_pIndieC were prepared in human PBMC; nAb titers against the remaining HIV strains were performed using pseudoviruses generated in transfected 293 T cells. All neutralization assays were performed at least in duplicate.

ISSN: 1742-4690